{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T15:13:36Z","timestamp":1793978016204,"version":"4.8.0"},"reference-count":190,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The introduction of immune checkpoint inhibitors (ICIs) has revolutionized cancer therapy, offering durable responses in multiple malignancies by targeting regulatory pathways such as programmed cell death protein 1 (PD-1), its ligand (PD-L1), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). These pathways, which normally maintain immune tolerance and homeostasis, can be exploited by tumors to evade immune surveillance. Dual blockade using monoclonal antibodies (mAbs) targeting PD-1\/PD-L1 and CTLA-4 has shown synergistic effects, improving response rates, overall survival, and progression-free survival in several cancer types. The U.S. Food and Drug Administration (FDA) has approved two such combinations: nivolumab plus ipilimumab and durvalumab plus tremelimumab, based on demonstrated clinical benefit in melanoma, renal cell carcinoma, colorectal cancer, hepatocellular carcinoma, non-small cell lung cancer, pleural mesothelioma, and esophageal squamous cell carcinoma. However, clinical benefit has not been consistent across all tumor types, with limited efficacy observed in cancers such as glioblastoma, head and neck squamous cell carcinoma, and Merkel cell carcinoma. Additionally, combination therapy is associated with a higher incidence of immune-related adverse events, affecting multiple organ systems and necessitating careful dosing strategies to balance efficacy and toxicity. This review summarizes the current landscape of FDA-approved PD-1\/PD-L1 and CTLA-4 combinations, their therapeutic achievements, clinical limitations, and supports future research in combination immunotherapy.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1680838","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T05:27:57Z","timestamp":1760333277000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":61,"title":["Combination of PD-1\/PD-L1 and CTLA-4 inhibitors in the treatment of cancer \u2013 a brief update"],"prefix":"10.3389","volume":"16","author":[{"given":"Johan","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f8rn Steen","family":"Sk\u00e5lhegg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity\u2019s roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2703","article-title":"Innate and adaptive immune cells in the tumor microenvironment","volume":"14","author":"Gajewski","year":"2013","journal-title":"Nat Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2023.09.011","article-title":"The cancer-immunity cycle: Indication, genotype, and immunotype","volume":"56","author":"Mellman","year":"2023","journal-title":"Immunity"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.coi.2014.01.004","article-title":"New insights into cancer immunoediting and its three component phases \u2014 elimination, equilibrium and escape","volume":"27","author":"Mittal","year":"2014","journal-title":"Curr Opin Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.17179\/excli2021-3522","article-title":"Co-stimulatory agonists: An insight into the immunotherapy of cancer","volume":"20","author":"Pourakbari","year":"2021","journal-title":"EXCLI J"},{"key":"B7","doi-asserted-by":"publisher","first-page":"13110","DOI":"10.1038\/srep13110","article-title":"Development of PD-1\/PD-L1 pathway in tumor immune microenvironment and treatment for non-small cell lung cancer","volume":"5","author":"He","year":"2015","journal-title":"Sci Rep"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.168","article-title":"PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas","volume":"14","author":"Goodman","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"034002","DOI":"10.1088\/2057-1739\/aa7e86","article-title":"Dynamic interplay between tumour, stroma and immune system can drive or prevent tumour progression","volume":"3","author":"Seager","year":"2017","journal-title":"Converg Sci Phys Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00086","article-title":"Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations","volume":"8","author":"Seidel","year":"2018","journal-title":"Front Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.intimp.2018.06.001","article-title":"Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors","volume":"62","author":"Hargadon","year":"2018","journal-title":"Int Immunopharmacology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1093\/annonc\/mdx686","article-title":"Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy","volume":"29","author":"Rotte","year":"2018","journal-title":"Ann Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1159\/000503254","article-title":"Scientific rationale for combination immunotherapy of hepatocellular carcinoma with anti-PD-1\/PD-L1 and anti-CTLA-4 antibodies","volume":"8","author":"Kudo","year":"2019","journal-title":"Liver Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.07.024","article-title":"Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade","volume":"170","author":"Wei","year":"2017","journal-title":"Cell"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)80406-9","article-title":"Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells","volume":"7","author":"Chambers","year":"1997","journal-title":"Immunity"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S1471-4906(01)01888-9","article-title":"PD-1: an inhibitory immunoreceptor involved in peripheral tolerance","volume":"22","author":"Nishimura","year":"2001","journal-title":"Trends Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.25.21.9543-9553.2005","article-title":"CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms","volume":"25","author":"Parry","year":"2005","journal-title":"Mol Cell Biol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0915174107","article-title":"PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors","volume":"107","author":"Curran","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e3181c01fcb","article-title":"Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy","volume":"33","author":"Mangsbo","year":"2010","journal-title":"J Immunother"},{"key":"B20","unstructured":"Drugs@FDA: FDA-Approved Drugs"},{"key":"B21","article-title":"Oncology (Cancer)\/Hematologic Malignancies Approval Notifications","year":"2025"},{"key":"B22","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/gene.2013.57","article-title":"Differential CTLA-4 expression in human CD4+ versus CD8+ T cells is associated with increased NFAT1 and inhibition of CD4+ proliferation","volume":"15","author":"Chan","year":"2014","journal-title":"Genes Immun"},{"key":"B23","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1189\/jlb.1212621","article-title":"At the Bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy","volume":"94","author":"Intlekofer","year":"2013","journal-title":"J Leukoc Biol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-0488-6","article-title":"The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications","volume":"17","author":"Zhang","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1126\/science.7694361","article-title":"Identification of an alternative CTLA-4 ligand costimulatory for T cell activation","volume":"262","author":"Hathcock","year":"1993","journal-title":"Science"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1126\/science.7694363","article-title":"Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation","volume":"262","author":"Freeman","year":"1993","journal-title":"Science"},{"key":"B27","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/j.1600-065X.2009.00770.x","article-title":"CD28 and CTLA-4 coreceptor expression and signal transduction","volume":"229","author":"Rudd","year":"2009","journal-title":"Immunol Rev"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1084\/jem.182.2.459","article-title":"CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation","volume":"182","author":"Krummel","year":"1995","journal-title":"J Exp Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/1074-7613(94)90071-X","article-title":"CTLA-4 can function as a negative regulator of T cell activation","volume":"1","author":"Walunas","year":"1994","journal-title":"Immunity"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1126\/science.1202947","article-title":"Trans-endocytosis of CD80 and CD86: a molecular basis for the cell extrinsic function of CTLA-4","volume":"332","author":"Qureshi","year":"2011","journal-title":"Science"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1126\/science.1160062","article-title":"CTLA-4 control over Foxp3+ regulatory T cell function","volume":"322","author":"Wing","year":"2008","journal-title":"Science"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20082492","article-title":"Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies","volume":"206","author":"Peggs","year":"2009","journal-title":"J Exp Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.108","article-title":"The diverse functions of the PD1 inhibitory pathway","volume":"18","author":"Sharpe","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune checkpoint blockade in cancer therapy","volume":"33","author":"Postow","year":"2015","journal-title":"J Clin Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J Exp Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20051776","article-title":"Tissue expression of PD-L1 mediates peripheral T cell tolerance","volume":"203","author":"Keir","year":"2006","journal-title":"J Exp Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida","year":"1992","journal-title":"EMBO J"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/70932","article-title":"B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion","volume":"5","author":"Dong","year":"1999","journal-title":"Nat Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/85330","article-title":"PD-L2 is a second ligand for PD-1 and inhibits T cell activation","volume":"2","author":"Latchman","year":"2001","journal-title":"Nat Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2019.09.030","article-title":"Mechanisms controlling PD-L1 expression in cancer","volume":"76","author":"Cha","year":"2019","journal-title":"Mol Cell"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1172\/JCI126022","article-title":"IL-6\/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion","volume":"129","author":"Chan","year":"2019","journal-title":"J Clin Invest"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2567.2012.03591.x","article-title":"Regulation of TCR signalling by tyrosine phosphatases: from immune homeostasis to autoimmunity","volume":"137","author":"Stanford","year":"2012","journal-title":"Immunology"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2009.00767.x","article-title":"PD-1 signaling in primary T cells","volume":"229","author":"Riley","year":"2009","journal-title":"Immunol Rev"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/nature04444","article-title":"Restoring function in exhausted CD8 T cells during chronic viral infection","volume":"439","author":"Barber","year":"2006","journal-title":"Nature"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"N Engl J Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N Engl J Med"},{"key":"B47","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00545-3","article-title":"Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study","volume":"22","author":"Tawbi","year":"2021","journal-title":"Lancet Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1046","article-title":"Primary analysis and 4-year follow-up of the phase III NIBIT-M2 trial in melanoma patients with brain metastases","volume":"27","author":"Di Giacomo","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30417-7","article-title":"Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"395","author":"Zimmer","year":"2020","journal-title":"Lancet"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00533","article-title":"Adjuvant therapy of nivolumab combined with ipilimumab versus nivolumab alone in patients with resected stage IIIB-D or stage IV melanoma (CheckMate 915)","volume":"41","author":"Weber","year":"2023","journal-title":"J Clin Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2402604","article-title":"Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma","volume":"391","author":"Blank","year":"2024","journal-title":"N Engl J Med"},{"key":"B53","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1200\/JCO.20.00605","article-title":"Nivolumab and ipilimumab in metastatic uveal melanoma: results from a single-arm phase II study","volume":"39","author":"Pelster","year":"2021","journal-title":"J Clin Oncol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00550","article-title":"Nivolumab plus ipilimumab for treatment-na\u00efve metastatic uveal melanoma: an open-label, multicenter, phase II trial by the spanish multidisciplinary melanoma group (GEM-1402)","volume":"39","author":"Piulats","year":"2021","journal-title":"J Clin Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30428-X","article-title":"Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial","volume":"18","author":"Long","year":"2017","journal-title":"Lancet Oncol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30366-7","article-title":"Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial","volume":"17","author":"Hodi","year":"2016","journal-title":"Lancet Oncol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa2407417","article-title":"Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma","volume":"392","author":"Wolchok","year":"2025","journal-title":"N Engl J Med"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02229","article-title":"Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma","volume":"40","author":"Wolchok","year":"2022","journal-title":"J Clin Oncol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30700-9","article-title":"Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial","volume":"19","author":"Hodi","year":"2018","journal-title":"Lancet Oncol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01998","article-title":"Evaluation of two dosing regimens for nivolumab in combination with ipilimumab in patients with advanced melanoma: results from the phase IIIb\/IV checkMate 511 trial","volume":"37","author":"Lebb\u00e9","year":"2019","journal-title":"J Clin Oncol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1256800","article-title":"Outcome and treatment-related adverse events of combined immune checkpoint inhibition with flipped dosing in a real-world cohort of 79 patients with metastasized melanoma","volume":"13","author":"N\u00fcbel","year":"2023","journal-title":"Front Oncol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ejca.2017.01.009","article-title":"Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma","volume":"75","author":"Zimmer","year":"2017","journal-title":"Eur J Cancer"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003853","article-title":"Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses","volume":"10","author":"Friedman","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01763","article-title":"Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced BRAF-mutant melanoma: the DREAMseq trial-ECOG-ACRIN EA6134","volume":"41","author":"Atkins","year":"2023","journal-title":"J Clin Oncol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02199","article-title":"First-line, fixed-duration nivolumab plus ipilimumab followed by nivolumab in clinically diverse patient populations with unresectable stage III or IV melanoma: checkMate 401","volume":"41","author":"Dummer","year":"2023","journal-title":"J Clin Oncol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1007\/s00432-024-05981-2","article-title":"Quality of life under treatment with the immune checkpoint inhibitors ipilimumab and nivolumab in melanoma patients. Real-world data from a prospective observational study at the Skin Cancer Center Kiel","volume":"150","author":"Grote","year":"2024","journal-title":"J Cancer Res Clin Oncol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15514","article-title":"Final analysis of a phase II study of nivolumab in combination with ipilimumab for unresectable chemotherapy-naive advanced melanoma","volume":"47","author":"Namikawa","year":"2020","journal-title":"J Dermatol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02498-y","article-title":"Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial","volume":"29","author":"VanderWalde","year":"2023","journal-title":"Nat Med"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30126-7","article-title":"Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial","volume":"17","author":"Weber","year":"2016","journal-title":"Lancet Oncol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30139-6","article-title":"Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study","volume":"19","author":"Long","year":"2018","journal-title":"Lancet Oncol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00735-6","article-title":"Ipilimumab plus nivolumab versus nivolumab alone in patients with melanoma brain metastases (ABC): 7-year follow-up of a multicentre, open-label, randomised, phase 2 study","volume":"26","author":"Long","year":"2025","journal-title":"Lancet Oncol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"113531","DOI":"10.1016\/j.ejca.2024.113531","article-title":"Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial","volume":"199","author":"Di Giacomo","year":"2024","journal-title":"Eur J Cancer"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805453","article-title":"Combined nivolumab and ipilimumab in melanoma metastatic to the brain","volume":"379","author":"Tawbi","year":"2018","journal-title":"N Engl J Med"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab094","article-title":"Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)","volume":"23","author":"Tawbi","year":"2021","journal-title":"Neuro Oncol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0198-0","article-title":"Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma","volume":"24","author":"Blank","year":"2018","journal-title":"Nat Med"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0197-1","article-title":"Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma","volume":"24","author":"Amaria","year":"2018","journal-title":"Nat Med"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30151-2","article-title":"Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial","volume":"20","author":"Rozeman","year":"2019","journal-title":"Lancet Oncol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00079","article-title":"Pembrolizumab plus ipilimumab following anti-PD-1\/L1 failure in melanoma","volume":"39","author":"Olson","year":"2021","journal-title":"J Clin Oncol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.72.1985","article-title":"Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: the checkMate 016 study","volume":"35","author":"Hammers","year":"2017","journal-title":"J Clin Oncol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"B83","doi-asserted-by":"publisher","first-page":"104073","DOI":"10.1016\/j.esmoop.2024.104073","article-title":"Nivolumab plus relatlimab and nivolumab plus ipilimumab for patients with advanced renal cell carcinoma: results from the open-label, randomised, phase II FRACTION-RCC trial","volume":"9","author":"Choueiri","year":"2024","journal-title":"ESMO Open"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003844","article-title":"Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b\/4 CheckMate 920 trial","volume":"10","author":"Tykodi","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2019.11.012","article-title":"Clinical activity of ipilimumab plus nivolumab in patients with metastatic non-clear cell renal cell carcinoma","volume":"18","author":"Gupta","year":"2020","journal-title":"Clin Genitourin Cancer"},{"key":"B86","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/bju.16190","article-title":"A phase II trial of nivolumab followed by ipilimumab and nivolumab in advanced non-clear-cell renal cell carcinoma","author":"Conduit","year":"2024","journal-title":"BJU Int"},{"key":"B87","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/S1470-2045(18)30778-2","article-title":"Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial","volume":"20","author":"Cella","year":"2019","journal-title":"Lancet Oncol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2020-001079","article-title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial","volume":"5","author":"Albiges","year":"2020","journal-title":"ESMO Open"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.07.727","article-title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial","volume":"35","author":"Tannir","year":"2024","journal-title":"Ann Oncol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00449-7","article-title":"Tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma (TITAN-RCC): a multicentre, single-arm, phase 2 trial","volume":"24","author":"Grimm","year":"2023","journal-title":"Lancet Oncol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.9901","article-title":"Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient\/microsatellite instability-high metastatic colorectal cancer","volume":"36","author":"Overman","year":"2018","journal-title":"J Clin Oncol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2402141","article-title":"Nivolumab plus ipilimumab in microsatellite-instability-high metastatic colorectal cancer","volume":"391","author":"Andre","year":"2024","journal-title":"N Engl J Med"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)02848-4","article-title":"Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial","volume":"405","author":"Andr\u00e9","year":"2025","journal-title":"Lancet"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0805-8","article-title":"Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers","volume":"26","author":"Chalabi","year":"2020","journal-title":"Nat Med"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30422-9","article-title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study","volume":"18","author":"Overman","year":"2017","journal-title":"Lancet Oncol"},{"key":"B96","article-title":"FDA grants accelerated approval to ipilimumab for MSI-H or dMMR metastatic colorectal cancer","year":"2019"},{"key":"B97","article-title":"FDA approves nivolumab with ipilimumab for unresectable or metastatic MSI-H or dMMR colorectal cancer","year":"2025"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.4564","article-title":"Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the checkMate 040 randomized clinical trial","volume":"6","author":"Yau","year":"2020","journal-title":"JAMA Oncol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)00403-9","article-title":"Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial","volume":"405","author":"Yau","year":"2025","journal-title":"Lancet"},{"key":"B100","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.1200\/JCO.20.03555","article-title":"Safety, efficacy, and pharmacodynamics of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma: randomized expansion of a phase I\/II study","volume":"39","author":"Kelley","year":"2021","journal-title":"J Clin Oncol"},{"key":"B101","doi-asserted-by":"publisher","first-page":"EVIDoa2100070","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.03.005","article-title":"Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040","volume":"35","author":"Melero","year":"2024","journal-title":"Ann Oncol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-025-02978-7","article-title":"Prompt initiation of durvalumab and tremelimumab for unresectable hepatocellular carcinoma in patients with chronic active hepatitis B: a phase 2 clinical trial","volume":"132","author":"Shao","year":"2025","journal-title":"Br J Cancer"},{"key":"B104","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(16)30624-6","article-title":"Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study","volume":"18","author":"Hellmann","year":"2017","journal-title":"Lancet Oncol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801946","article-title":"Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden","volume":"378","author":"Hellmann","year":"2018","journal-title":"N Engl J Med"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N Engl J Med"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.2209","article-title":"Nivolumab plus ipilimumab vs nivolumab for previously treated patients with stage IV squamous cell lung cancer: the lung-MAP S1400I phase 3 randomized clinical trial","volume":"7","author":"Gettinger","year":"2021","journal-title":"JAMA Oncol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-02239","article-title":"Neoadjuvant nivolumab plus ipilimumab versus chemotherapy in resectable lung cancer","volume":"43","author":"Awad","year":"2025","journal-title":"J Clin Oncol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.0237","article-title":"Durvalumab with or without tremelimumab vs standard chemotherapy in first-line treatment of metastatic non-small cell lung cancer: the MYSTIC phase 3 randomized clinical trial","volume":"6","author":"Rizvi","year":"2020","journal-title":"JAMA Oncol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2022.09.223","article-title":"NEPTUNE: phase 3 study of first-line durvalumab plus tremelimumab in patients with metastatic NSCLC","volume":"18","author":"de Castro","year":"2023","journal-title":"J Thorac Oncol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.02.006","article-title":"ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer","volume":"31","author":"Planchard","year":"2020","journal-title":"Ann Oncol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03579","article-title":"Pembrolizumab plus ipilimumab or placebo for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score \u2265 50%: randomized, double-blind phase III KEYNOTE-598 study","volume":"39","author":"Boyer","year":"2021","journal-title":"J Clin Oncol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.10.004","article-title":"Nivolumab monotherapy and nivolumab plus ipilimumab in recurrent small cell lung cancer: results from the checkMate 032 randomized cohort","volume":"15","author":"Ready","year":"2020","journal-title":"J Thorac Oncol"},{"key":"B114","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1200\/JCO.18.01042","article-title":"First-line nivolumab plus ipilimumab in advanced non-small-cell lung cancer (CheckMate 568): outcomes by programmed death ligand 1 and tumor mutational burden as biomarkers","volume":"37","author":"Ready","year":"2019","journal-title":"J Clin Oncol"},{"key":"B115","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.jtho.2021.09.010","article-title":"First-line nivolumab plus ipilimumab in advanced NSCLC: 4-year outcomes from the randomized, open-label, phase 3 checkMate 227 part 1 trial","volume":"17","author":"Paz-Ares","year":"2022","journal-title":"J Thorac Oncol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01503","article-title":"Five-year survival outcomes with nivolumab plus ipilimumab versus chemotherapy as first-line treatment for metastatic non\u2013small-cell lung cancer in checkMate 227","volume":"41","author":"Brahmer","year":"2023","journal-title":"J Clin Oncol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.12.019","article-title":"First-line nivolumab plus ipilimumab versus chemotherapy in advanced NSCLC with 1% or greater tumor PD-L1 expression: patient-reported outcomes from checkMate 227 part 1","volume":"16","author":"Reck","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-01224-2","article-title":"Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial","volume":"27","author":"Cascone","year":"2021","journal-title":"Nat Med"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyad195","article-title":"First-line nivolumab plus ipilimumab with or without chemotherapy for Japanese patients with non-small cell lung cancer: LIGHT-NING study","volume":"54","author":"Imai","year":"2024","journal-title":"Jpn J Clin Oncol"},{"key":"B120","doi-asserted-by":"publisher","first-page":"100394","DOI":"10.1016\/j.esmoop.2022.100394","article-title":"First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients","volume":"7","author":"O\u2019Byrne","year":"2022","journal-title":"ESMO Open"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.01.074","article-title":"First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable Malignant pleural mesothelioma: 3-year outcomes from CheckMate 743","volume":"33","author":"Peters","year":"2022","journal-title":"Ann Oncol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.05.008","article-title":"Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial","volume":"116","author":"Reck","year":"2019","journal-title":"Eur J Cancer"},{"key":"B123","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S1470-2045(15)00544-6","article-title":"Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study","volume":"17","author":"Antonia","year":"2016","journal-title":"Lancet Oncol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2023.04.020","article-title":"Brief report: safety and antitumor activity of durvalumab plus tremelimumab in programmed cell death-(Ligand)1-monotherapy pretreated, advanced NSCLC: results from a phase 1b clinical trial","volume":"18","author":"Garon","year":"2023","journal-title":"J Thorac Oncol"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002973","article-title":"Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1\/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760)","volume":"9","author":"Leighl","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B126","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.cllc.2021.02.010","article-title":"Patient-reported outcomes with durvalumab with or without tremelimumab versus standard chemotherapy as first-line treatment of metastatic non-small-cell lung cancer (MYSTIC)","volume":"22","author":"Garon","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"B127","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.lungcan.2018.12.015","article-title":"Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non-small-cell lung cancer: KEYNOTE-021 cohorts D and H","volume":"130","author":"Gubens","year":"2019","journal-title":"Lung Cancer"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30098-5","article-title":"Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1\/2 trial","volume":"17","author":"Antonia","year":"2016","journal-title":"Lancet Oncol"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02212","article-title":"Nivolumab and ipilimumab as maintenance therapy in extensive-disease small-cell lung cancer: checkMate 451","volume":"39","author":"Owonikoko","year":"2021","journal-title":"J Clin Oncol"},{"key":"B130","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.annonc.2021.09.011","article-title":"Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy - results from the randomised phase II ETOP\/IFCT 4\u201312 STIMULI trial","volume":"33","author":"Peters","year":"2022","journal-title":"Ann Oncol"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(18)30420-X","article-title":"Ipilimumab and nivolumab in the treatment of recurrent Malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial","volume":"7","author":"Disselhorst","year":"2019","journal-title":"Lancet Respir Med"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30765-4","article-title":"Nivolumab or nivolumab plus ipilimumab in patients with relapsed Malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial","volume":"20","author":"Scherpereel","year":"2019","journal-title":"Lancet Oncol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable Malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(18)30151-6","article-title":"Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study","volume":"6","author":"Calabr\u00f2","year":"2018","journal-title":"Lancet Respir Med"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-2566","article-title":"A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma","volume":"29","author":"Lee","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2111380","article-title":"Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma","volume":"386","author":"Doki","year":"2022","journal-title":"N Engl J Med"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4593","article-title":"Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head-and-neck cancer","volume":"11","author":"Doki","year":"2022","journal-title":"Cancer Med"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-2182","article-title":"A multicenter phase II trial of ipilimumab and nivolumab in unresectable or metastatic metaplastic breast cancer: cohort 36 of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART, SWOG S1609)","volume":"28","author":"Adams","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03249-3","article-title":"Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial","volume":"30","author":"Nederlof","year":"2024","journal-title":"Nat Med"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nox208","article-title":"Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143","volume":"20","author":"Omuro","year":"2018","journal-title":"Neuro Oncol"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002296","article-title":"Intracerebral administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in patients with recurrent glioblastoma: a phase I clinical trial","volume":"9","author":"Duerinck","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B142","doi-asserted-by":"publisher","first-page":"2432728","DOI":"10.1080\/2162402X.2024.2432728","article-title":"Pre-radiation Nivolumab plus ipilimumab in patients with newly diagnosed high-grade gliomas","volume":"13","author":"Kesari","year":"2024","journal-title":"Oncoimmunology"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00332","article-title":"Nivolumab plus ipilimumab versus EXTREME regimen as first-line treatment for recurrent\/metastatic squamous cell carcinoma of the head and neck: the final results of checkMate 651","volume":"41","author":"Haddad","year":"2023","journal-title":"J Clin Oncol"},{"key":"B144","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1001\/jamaoncol.2018.4628","article-title":"Safety and efficacy of durvalumab with or without tremelimumab in patients with PD-L1-low\/negative recurrent or metastatic HNSCC: the phase 2 CONDOR randomized clinical trial","volume":"5","author":"Siu","year":"2019","journal-title":"JAMA Oncol"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.04.001","article-title":"Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study","volume":"31","author":"Ferris","year":"2020","journal-title":"Ann Oncol"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.12.008","article-title":"Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study","volume":"34","author":"Psyrri","year":"2023","journal-title":"Ann Oncol"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.0147","article-title":"Efficacy and safety of nivolumab plus ipilimumab vs nivolumab alone for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck: the phase 2 checkMate 714 randomized clinical trial","volume":"9","author":"Harrington","year":"2023","journal-title":"JAMA Oncol"},{"key":"B148","doi-asserted-by":"publisher","first-page":"7348","DOI":"10.1038\/s41467-021-26472-9","article-title":"Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma","volume":"12","author":"Vos","year":"2021","journal-title":"Nat Commun"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.2955","article-title":"Neoadjuvant nivolumab or nivolumab plus ipilimumab in untreated oral cavity squamous cell carcinoma: A phase 2 open-label randomized clinical trial","volume":"6","author":"Schoenfeld","year":"2020","journal-title":"JAMA Oncol"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-3249","article-title":"A phase II open-label randomized clinical trial of preoperative durvalumab or durvalumab plus tremelimumab in resectable head and neck squamous cell carcinoma","volume":"30","author":"Kim","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01659-2","article-title":"Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial","volume":"400","author":"Kim","year":"2022","journal-title":"Lancet"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-02138","article-title":"Nivolumab with or without ipilimumab in patients with recurrent or metastatic merkel cell carcinoma: A nonrandomized, open-label, international, multicenter phase I\/II study","volume":"43","author":"Bhatia","year":"2025","journal-title":"J Clin Oncol"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02059","article-title":"Randomized phase II trial of nivolumab versus nivolumab and ipilimumab for recurrent or persistent ovarian cancer: an NRG oncology study","volume":"38","author":"Zamarin","year":"2020","journal-title":"J Clin Oncol"},{"key":"B154","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.medj.2024.02.003","article-title":"Phase 1b study of intraperitoneal ipilimumab and nivolumab in patients with recurrent gynecologic Malignancies with peritoneal carcinomatosis","volume":"5","author":"Knisely","year":"2024","journal-title":"Med"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35126","article-title":"Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum-resistant ovarian cancer","volume":"130","author":"Hinchcliff","year":"2024","journal-title":"Cancer"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.25564","article-title":"Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer","volume":"9","author":"Boudadi","year":"2018","journal-title":"Oncotarget"},{"key":"B157","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.ccell.2020.08.007","article-title":"Nivolumab plus ipilimumab for metastatic castration-resistant prostate cancer: preliminary analysis of patients in the checkMate 650 trial","volume":"38","author":"Sharma","year":"2020","journal-title":"Cancer Cell"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30006-8","article-title":"Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials","volume":"19","author":"D\u2019Angelo","year":"2018","journal-title":"Lancet Oncol"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002990","article-title":"Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)","volume":"9","author":"Wagner","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.03.012","article-title":"Phase II single-arm study of nivolumab and ipilimumab (Nivo\/Ipi) in previously treated classical Kaposi sarcoma (cKS)","volume":"33","author":"Zer","year":"2022","journal-title":"Ann Oncol"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00392-8","article-title":"Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial","volume":"23","author":"Somaiah","year":"2022","journal-title":"Lancet Oncol"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-2164","article-title":"A phase I\/II trial of nivolumab plus ipilimumab in children and young adults with relapsed\/refractory solid tumors: A children\u2019s oncology group study ADVL1412","volume":"28","author":"Davis","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00538","article-title":"Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg\/kg Plus Ipilimumab 3 mg\/kg Expansion Cohort Results","volume":"37","author":"Sharma","year":"2019","journal-title":"J Clin Oncol"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00053-0","article-title":"Tailored immunotherapy approach with nivolumab with or without ipilimumab in patients with advanced transitional cell carcinoma after platinum-based chemotherapy (TITAN-TCC): a multicentre, single-arm, phase 2 trial","volume":"24","author":"Grimm","year":"2023","journal-title":"Lancet Oncol"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02199-y","article-title":"High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial","volume":"29","author":"van Dorp","year":"2023","journal-title":"Nat Med"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1085-z","article-title":"Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial","volume":"26","author":"van Dijk","year":"2020","journal-title":"Nat Med"},{"key":"B167","doi-asserted-by":"publisher","first-page":"CT112","DOI":"10.1158\/1538-7445.AM2018-CT112","article-title":"Abstract CT112: Durvalumab + tremelimumab in patients with metastatic urothelial cancer","volume":"78","author":"Balar","year":"2018","journal-title":"Cancer Res"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30541-6","article-title":"Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1086-y","article-title":"Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma","volume":"26","author":"Gao","year":"2020","journal-title":"Nat Med"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-018-0735-0","article-title":"Adverse event profiles of anti-CTLA-4 and anti-PD-1 monoclonal antibodies alone or in combination: analysis of spontaneous reports submitted to FAERS","volume":"39","author":"Ji","year":"2019","journal-title":"Clin Drug Investig"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.1611","article-title":"Immune checkpoint inhibitors and immune-related adverse events in patients with advanced melanoma: A systematic review and network meta-analysis","volume":"3","author":"Chang","year":"2020","journal-title":"JAMA Netw Open"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"B173","doi-asserted-by":"publisher","first-page":"10948","DOI":"10.3390\/ijms231810948","article-title":"Cardiac toxicity associated with immune checkpoint inhibitors: A systematic review","volume":"23","author":"Cozma","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1167975","article-title":"Immune-related adverse events of immune checkpoint inhibitors: a review","volume":"14","author":"Yin","year":"2023","journal-title":"Front Immunol"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.07.015","article-title":"Associations between patient and disease characteristics and severe adverse events during immune checkpoint inhibitor treatment: An observational study","volume":"174","author":"Basak","year":"2022","journal-title":"Eur J Cancer"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1016\/j.pccm.2023.08.002","article-title":"Pathogenesis, pathological characteristics and individualized therapy for immune-related adverse effects","volume":"1","author":"Miao","year":"2023","journal-title":"Chin Med J Pulmonary Crit Care Med"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx286","article-title":"Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review","volume":"28","author":"Khoja","year":"2017","journal-title":"Ann Oncol"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00333-8","article-title":"Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis","volume":"22","author":"Zhou","year":"2021","journal-title":"Lancet Oncol"},{"key":"B180","doi-asserted-by":"publisher","first-page":"1748982","DOI":"10.1080\/2162402X.2020.1748982","article-title":"Dose dependence of treatment-related adverse events for immune checkpoint inhibitor therapies: a model-based meta-analysis","volume":"9","author":"Shulgin","year":"","journal-title":"Oncoimmunology"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor mutational burden and response rate to PD-1 inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N Engl J Med"},{"key":"B182","doi-asserted-by":"publisher","first-page":"112470","DOI":"10.1016\/j.biopha.2021.112470","article-title":"Biomarkers related to immune checkpoint inhibitors therapy","volume":"147","author":"Li","year":"2022","journal-title":"Biomedicine Pharmacotherapy"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3054","article-title":"Tumor mutational burden as a predictor of immunotherapy response: is more always better","volume":"27","author":"Strickler","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B184","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.3390\/cancers13123063","article-title":"Microsatellite instability in colorectal cancers: carcinogenesis, neo-antigens, immuno-resistance and emerging therapies","volume":"13","author":"Randrian","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B185","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1016\/j.cell.2020.01.032","article-title":"Passenger mutations in more than 2,500 cancer genomes: overall molecular functional impact and consequences","volume":"180","author":"Kumar","year":"2020","journal-title":"Cell"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1200\/PO.17.00073","article-title":"Landscape of microsatellite instability across 39 cancer types","volume":"2017","author":"Bonneville","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1159\/000438523","article-title":"Prognostic role of tumor-infiltrating lymphocytes in lung cancer: a meta-analysis","volume":"37","author":"Geng","year":"2015","journal-title":"Cell Physiol Biochem"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.11306","article-title":"The regulation of immune checkpoints by the hypoxic tumor microenvironment","volume":"9","author":"Hu","year":"2021","journal-title":"PeerJ"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00566-3","article-title":"Interferon-\u03b3: teammate or opponent in the tumour microenvironment","volume":"22","author":"Gocher","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"B190","doi-asserted-by":"publisher","first-page":"3331","DOI":"10.3390\/cancers12113331","article-title":"Cancer extracellular matrix proteins regulate tumour immunity","volume":"12","author":"Gordon-Weeks","year":"2020","journal-title":"Cancers (Basel)"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1680838\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T05:27:59Z","timestamp":1760333279000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1680838\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,13]]},"references-count":190,"alternative-id":["10.3389\/fimmu.2025.1680838"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1680838","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,13]]},"article-number":"1680838"}}